Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR was used to measure CDH13 expression in lung cancer A549 and A549/DDP cells with or without 5-Aza-CdR intervention.
|
30344726 |
2018 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We examined the methylation status of the CDH13 promoter in breast and lung cancers and correlated it with mRNA expression using methylation-specific PCR and reverse transcription-PCR.
|
11389090 |
2001 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer.
|
25735345 |
2015 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined the frequency of aberrant promoter methylation of the p16, adenomatous polyposis coli (APC), H-cadherin (CDH13), glutathione S-transferase P1 (GSTP1), O6-methylguanine-DNA-methyltransferase (MGMT), retinoic acid receptor beta-2 (RAR beta), E-cadherin (CDH1), and RAS association domain family 1A (RASSF1A) genes in 198 tumors consisting of small cell lung cancers [SCLCs (n = 43)], non-small cell lung cancers [NSCLCs (n = 115)], and bronchial carcinoids (n = 40).
|
12467239 |
2001 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, the frequency of p16INK4A or CDH13 hypermethylation in patient serum, together with evidence of their early occurrence in lung cancerogenesis and the total lack of methylation in serum from healthy individuals, offer a promising tool for non invasive early detection of lung cancer.
|
16222700 |
2006 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggest that a combination of deletion and hypermethylation causes inactivation of the CDH13 gene in a considerable number of human lung cancers.
|
9737784 |
1998 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The methylation status of 6 genes, including a candidate tumor suppressor gene (BLU), the cadherin 13 gene (CDH13), the fragile histidine triad gene (FHIT), the cell cycle control gene p16, the retinoic acid receptor beta gene (RARbeta), and the Ras association domain family 1 gene (RASSF1A), was examined in plasma samples, corresponding tumor tissues, and normal lung tissues from a group of 63 patients with lung cancer and in plasma samples from 36 cancer-free individuals.
|
17876837 |
2007 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The methylation status of the promoter regions of the E-cadherin and H-cadherin genes was examined by using nested MSP in 88 primary lung cancers and paired adjacent normal tissues.
|
17960794 |
2007 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study examined the relationship between methylation of five genes (p16(INK4a), RASSF1A, APC, RARbeta and CDH13) and patient survival in 351 cases of surgically resected lung cancers.
|
15266335 |
2004 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Previously, we reported that the 5' region of CDH13 is frequently methylated in breast and lung cancers.
|
12067979 |
2002 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined 514 cases of NSCLC and 84 corresponding nonmalignant lung tissues from 4 countries (USA, Australia, Japan and Taiwan) for the methylation status of 7 genes known to be frequently methylated in lung cancers [p16, RASSF1A (RAS association domain family 1), APC, RARbeta, CDH13, MGMT and GSTP1].
|
12455028 |
2003 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation status of p16(INK4a), RASSF1A, APC, RARbeta, and CDH13, frequently methylated in lung cancer, was determined by methylation-specific PCR and the degree of methylation was defined as the methylation index.
|
16452191 |
2006 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation in CDH13 and MGMT was associated with clinicopathologic features of NSCLC.
|
22169480 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
In the present study, promoter hypermethylation of p16INK4A and CDH13 genes was investigated in tumor tissue and in matched serum from 61 patients with histologically confirmed non-small cell lung cancer.
|
16222700 |
2006 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
We examined 514 cases of NSCLC and 84 corresponding nonmalignant lung tissues from 4 countries (USA, Australia, Japan and Taiwan) for the methylation status of 7 genes known to be frequently methylated in lung cancers [p16, RASSF1A (RAS association domain family 1), APC, RARbeta, CDH13, MGMT and GSTP1].
|
12455028 |
2003 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
The rate of RASSF1A and CDH13 gene methylation in 42 cases of NSCLC patients was significantly higher than in 40 healthy controls (52.4% to 0.0%, 54.8% to 0.0%, p<0.05).
|
24998565 |
2014 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor.
|
18337602 |
2008 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The authors investigated the methylation status of the promoter region of human E-cadherin and H-cadherin genes in resected samples of primary nonsmall cell lung cancer (NSCLC) using methylation-specific polymerase chain reaction (MSP) analysis and correlated the results with clinicopathologic characteristics.
|
17960794 |
2007 |
Non-Small Cell Lung Carcinoma
|
0.380 |
PosttranslationalModification
|
disease |
BEFREE |
We determined the methylation of p16, CDH13 and RAR-beta which were reported to be methylated frequently in NSCLCs and HPP-1 which was known to be methylated in other types of cancers.
|
15201980 |
2004 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
|
12174885 |
2002 |
Liver carcinoma
|
0.350 |
PosttranslationalModification
|
disease |
BEFREE |
Upon pharmacological treatment with demethylating agent 5-aza-2'-deoxycytidine or histone deacetylase inhibitor trichostatin A, T-cadherin promoter hypermethylation and/or histone deacetylation was frequently observed in HCC samples and cell lines.
|
18553387 |
2008 |
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
H-cadherin (CDH13), protocadherin-10 (PCDH10), P-cadherin (CDH3), and M-cadherin (CDH15) methylation may have an increased risk of HCC in fewer than 4 studies, and methylated cadherin 8, type 2 (CDH8) and OB-cadherin (CDH11) had a similar OR in HCC and adjacent samples.
|
28422868 |
2017 |
Liver carcinoma
|
0.350 |
PosttranslationalModification
|
disease |
BEFREE |
In the HCC with T-cadherin promoter methylation, the T-cadherin expression was significantly decreased compared to HCC without methylation.
|
18425332 |
2008 |
Substance Use Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
CDH13 has been implicated previously in substance use disorders.
|
18821565 |
2008 |
Substance Use Disorders
|
0.330 |
GeneticVariation
|
group |
BEFREE |
A total of 110 adult patients with ASD (n=61) or ADHD (n=49) with or without a lifetime history of SUD participated in a study in which we genotyped polymorphisms in five known candidate genes for (one of) the disorders, i.e. the 5HTTLPR in SLC6A4/5-HTT, rs1800497 (TaqIA C>T) in DRD2, rs7794745 in CNTNAP2, rs1843809 in TPH2, and rs6565113 in CDH13.
|
20446882 |
2010 |